UNC2881
UNC2881 Basic information
- Product Name:
- UNC2881
- Synonyms:
-
- 2-(Butylamino)-4-[(trans-4-hydroxycyclohexyl)amino]-N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-5-pyrimidinecarboxamide
- UNC2881
- N-(4-(1H-iMidazol-1-yl)benzyl)-2-(butylaMino)-4-(((1r,4r)-4-hydroxycyclohexyl)aMino)pyriMidine-5-carboxaMide
- N-(4-(1H-imidazol-1-yl)benzyl)-2-(butylamino)-4-((1r,4r)-4-hydroxycyclohexylamino)pyrimidine-5-carboxamide UNC2881
- N-(4-(1H-Imidazol-1-yl)benzyl)-2-(butylamino)-4-(((1r,4r)-4-hydroxycyclohexyl)amino)pyrimidine
- 110849
- UNC 2881; UNC-2881
- CS-1177
- CAS:
- 1493764-08-1
- MF:
- C25H33N7O2
- MW:
- 463.58
- Product Categories:
-
- Inhibitors
- Mol File:
- 1493764-08-1.mol
UNC2881 Chemical Properties
- Density
- 1.31±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; insoluble in EtOH; ≥13.55 mg/mL in DMSO
- form
- solid
- pka
- 12.70±0.46(Predicted)
- color
- White to off-white
UNC2881 Usage And Synthesis
Description
UNC2881 is an inhibitor of Mer (IC50 = 4.3 nM), a member of the TAM family of receptor tyrosine kinases. It is selective for Mer over the remaining TAM family members Axl and TYRO3 (IC50s = 360 and 250 nM, respectively). UNC2881 inhibits phosphorylation of Mer in 697 B-ALL acute lymphoblastic leukemia cells (IC50 = 21.9 nM). It inhibits platelet aggregation and ATP release induced by type I equine fibrillar collagen in isolated human platelet-rich plasma when used at a concentration of 3 μM.
Uses
UNC2881 is a specific Mer tyrosine kinase inhibitor. It inhibits collagen-stimulated platelet aggregation.
in vivo
UNC2881 (3 mg/kg; p.o.; single dose) has high systemic clearance (94.5 mL/min/kg) and 14% oral bioavailability, displays terminal half-life of 0.80 h[1].
UNC2881 (3 mg/kg; i.v.; injected with VSV on days -3, -2, -1, and 0) limits Mertk signaling, and promotes the antiviral immune response, reducing the viral replication of vesicular stomatitis virus (VSV) in infected mice[2].
Pharmacokinetics of UNC2881 in mice[1]
| Route | Dose (mg/kg) | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUClast (ng·h/mL) | CLobs (mL/min) | Vss (L/kg) | F (%) |
| IV | 3 | 0.8 | 2609 | 527 | 94.5 | 1.65 | ||
| PO | 3 | 0.30 | 90.0 | 71.7 | 14 |
| Animal Model: | C57BL/6 mice (7-10 weeks old)[2] |
| Dosage: | 3 mg/kg |
| Administration: | Intravenous injection; infected with 2×108 PFU vesicular stomatitis virus (VSV) (i.v.) on days -3, -2, -1, and 0 |
| Result: | Reduced VSV replication in spleen, liver, kidney, lung. |
target
Mer tyrosine kinase
IC 50
Axl; Mer
storage
Store at +4°C
References
[1]. zhang w, mciver al, stashko ma, et al. discovery of mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. j med chem, 2013, 56(23): 9693-9700.
UNC2881Supplier
- Tel
- sales@boylechem.com
- Tel
- 0510-83588313-811 18800520310;
- sales@chemshuttle.com
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 021-58955995
- sales@medchemexpress.cn